1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.
Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
U.S. Physical Therapy entered a 45-month forward-starting interest rate swap with Bank of America on September 22, 2026, with an initial notional amount of $170.6 million. The swap fixes the variable interest rate on the term debt under its April 14, 2026 credit agreement, starting June 30, 2027, when its existing swap expires. The filing describes this as a hedge on borrowing costs, with no earnings figures disclosed.
Swap notional amount: $170.6 million, reflecting term loan amortization as of the effective date
Company pays a fixed rate of 4.578% per annum and receives one-month SOFR; swap effective June 30, 2027
Swap terminates April 14, 2031; Bank of America is counterparty and Administrative Agent under the credit agreement
The Trustee issued a release answering Unit Holder questions about administrative expenses, a 2017–2020 joint interest audit adjustment, Hilcorp capital spending, and liquidity. It states general and administrative expenses fell by about $976,000 year over year, mainly due to costs from the 2024 trustee transition that did not recur, and that the $2,000,000 Texas Bank credit facility, maturing May 21, 2027, is being discussed for extension, renewal, or replacement.
General and administrative expenses decreased by approximately $976,000 year over year, mainly from non-recurring 2024 trustee transition costs
Outstanding principal on the $2,000,000 Texas Bank Line of Credit was approximately $1,075,400 as of September 18, 2026; the facility matures May 21, 2027
The Trustee is in talks with Texas Bank and evaluating other financing sources, including other commercial lenders, Unit Holders, and private lenders
National newswire distribution of monthly press releases will be restored, beginning with the October 2026 release
Greenland Mines Ltd. agreed on September 28, 2026 to sell 1,320,000 shares of common stock in a direct registered offering to institutional investors, with expected net proceeds of about $17.2 million. The offering is expected to close on or about September 29, 2026, and the company plans to use the proceeds with existing cash for its Greenland mining operations and general working capital, which would add new shares outstanding and dilute existing holders.
1,320,000 shares of common stock offered; expected net proceeds of about $17.2 million after offering expenses
Expected closing on or about September 29, 2026, subject to customary closing conditions
On September 23, 2026, the company terminated its August 24, 2026 at-the-market sales agreement with A.G.P./Alliance Global Partners, under which $1,388,827.04 of shares had been sold
Wintergreen Acquisition Corp. issued a $184,635 non-interest-bearing promissory note to its sponsor, MACRO DREAM Holdings Limited, to fund a deposit into its trust account for an extension. The board approved extending the deadline for completing its business combination with KIKA Technology Inc. from September 30, 2026 to October 30, 2026, and the company says it continues to pursue that deal.
Note principal of $184,635 issued September 28, 2026 to sponsor MACRO DREAM Holdings Limited
Business combination deadline extended from September 30, 2026 to October 30, 2026
Sponsor may convert unpaid note principal into units at $10.00 per unit upon a business combination
Note is forgiven and the sponsor waives trust account claims if no business combination is completed
Ready Capital Corporation said its subsidiary ReadyCap Holdings II closed a private placement of $225.0 million of 10.00% senior secured notes due 2031 on September 28, 2026. On the same day, an indirect subsidiary redeemed the entire $350.0 million of its 4.50% senior secured notes due 2026 at 100% of principal plus accrued interest. The filing is a financing refinancing update and does not report revenue, earnings or guidance.
New Notes: $225.0 million aggregate principal, 10.00% coupon, due 2031, closed September 28, 2026
Existing Notes: entire $350.0 million 4.50% senior secured notes due 2026 redeemed September 28, 2026
Redemption price: 100% of principal amount plus accrued and unpaid interest
Offering was previously priced and disclosed in a Form 8-K filed September 18, 2026
OPENLANE's subsidiaries amended two receivables purchase facilities on September 25, 2026, extending the termination date of each from January 31, 2028 to January 31, 2030. The filing describes the extension as a term extension and does not mention new borrowing capacity, pricing changes, or costs.
U.S. facility: Second Amendment to the Tenth Amended and Restated Receivables Purchase Agreement, signed September 25, 2026, extends termination date to January 31, 2030
Canadian facility: Amendment No. 4 to the Receivables Purchase Agreement dated March 1, 2023, signed September 25, 2026, extends termination date to January 31, 2030
Full amendment texts will be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026
Voyager Technologies issued $402.5 million of 0% convertible senior notes due October 15, 2032, on September 28, 2026, including $52.5 million from the initial purchasers' full option exercise. The company reported net proceeds of approximately $391.6 million and plans to use about $52.5 million to fund capped call transactions, with the rest for general corporate purposes. Holders can convert into cash, Class A common stock, or a mix, which could dilute existing shareholders if the notes are converted into shares.
Principal: $402.5 million, including $52.5 million from the full exercise of the initial purchasers' option
Initial conversion price of approximately $40.82 per share, a premium of about 30% over the $31.40 close on September 23, 2026
Capped calls have a cap price of $78.50 per share and cost approximately $52.5 million
Net proceeds of approximately $391.6 million; the notes mature October 15, 2032
ADARx Pharmaceuticals closed its initial public offering on September 28, 2026, selling 26,250,000 shares at $17.00 each for approximately $446.3 million in gross proceeds. AbbVie bought 5,255,542 shares in a concurrent private placement for approximately $89.3 million in gross proceeds, leaving it with about 4.9% of outstanding common stock after the closings. The company also adopted an amended and restated certificate of incorporation and bylaws in connection with the IPO.
IPO closed September 28, 2026: 26,250,000 shares at $17.00 per share, approximately $446.3 million in gross proceeds.
AbbVie bought 5,255,542 shares in a private placement at the IPO price, approximately $89.3 million in gross proceeds, owning about 4.9% after closing.
Placement agent fee was 2.0% of the private placement purchase price; J.P. Morgan, Morgan Stanley, TD Securities, UBS and LifeSci Capital acted as agents.
Amended and restated certificate of incorporation and bylaws took effect September 28, 2026.
Cincinnati Financial and subsidiary CFC Investment Company extended the expiration date of their credit agreement by one year, to October 10, 2031, under a September 25, 2026 amendment. All other terms of the 2025 credit facility are unchanged, so the filing reports no new borrowing or change in amounts.
Extension signed September 25, 2026 with Fifth Third Bank, N.A. as administrative agent
Expiration date moved to October 10, 2031, a one-year extension of the prior expiration
Credit agreement originally dated October 10, 2025; all other terms unchanged
Churchill Downs closed an amendment to its senior secured credit agreement that extends its revolving credit facility and Term Loan A from 2029 to 2031. It also closed a new $500 million senior secured Term Loan B due 2033, which the company plans to use to repay existing term loan and revolver borrowings, fund fees, and for general corporate purposes. The filing does not report earnings or guidance, so its effect on shareholders depends on the terms of the new debt.
Revolver and Term Loan A maturities extended from 2029 to September 25, 2031
New $500 million Term Loan B due September 25, 2033, at SOFR plus 175 basis points, issued at 99.875% of principal
Net proceeds to repay term loan B-1 and revolving loans, pay fees and expenses, and for working capital
Company plans to fund redemption of its 5.50% Senior Notes due 2027 on October 19, 2026 from the revolver
RideNow Group entered a $220 million senior secured term loan with Centerbridge-affiliated lenders and Alter Domus, using proceeds to fully repay its 2021 Oaktree-agented credit agreement. The new loans mature in September 2031 but carry steep interest, and the company is in advanced talks for a $50 million ABL revolver with Wells Fargo that is not yet committed.
$220 million senior secured term loans due September 25, 2031, funded September 25, 2026 to refinance the Existing Credit Agreement with Oaktree
Interest at Base Rate plus 7.375% or Adjusted Term SOFR (3.00% floor) plus 8.375%
Financial covenants include a first-lien net leverage ratio up to 4.80 to 1.00 and minimum liquidity of $15 million
Three unsecured promissory notes totaling about $10.0 million, held by SH Capital Partners, Mark Tkach and Face Canyon, were amended with 13.0% PIK interest maturing August 31, 2028
Burke & Herbert Financial Services Corp. filed a preliminary prospectus supplement for a proposed $100 million offering of fixed-to-floating rate subordinated notes due 2036, under an existing shelf registration. The company plans to use the proceeds, plus cash on hand, to redeem up to $117.6 million of outstanding subordinated debt and up to $15.0 million of preferred stock, with the remainder for general corporate purposes, including capital for its bank.
Proposed offering size is $100 million; the notes have a 10-year term with a 5-year call, and Keefe, Bruyette & Woods is sole manager.
Expected rating is BBB- (Positive) from Kroll Bond Rating Agency.
Proceeds plus cash on hand would redeem up to $117.6 million of subordinated debt and up to $15.0 million of preferred stock liquidation preference.
Filing is dated September 28, 2026; the shelf registration was declared effective December 11, 2024, and an investor presentation is filed as Exhibit 99.1.
Fate Therapeutics said the California Institute for Regenerative Medicine awarded it a $15.0 million grant through its CLIN2 program to support the Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis. The filing does not state financial results or any change to company guidance, so the grant's direct effect on shareholders is not quantified.
CIRM awarded a $15.0 million grant on September 25, 2026, under its CLIN2 program.
The grant supports the Phase 2 RECLAIM-LN trial of FT819 in refractory lupus nephritis.
The trial is expected to enroll approximately 53 patients; the primary endpoint is complete renal response at Week 26.
Hut 8 Corp. entered into a $1.07 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent, dated September 24, 2026, with no amounts outstanding at closing. The company says the facility adds committed parent-level liquidity for interim working capital and letter of credit needs, which it describes as a way to fund projects while it decides on longer-term non-recourse financing.
Facility size: up to $1,070.0 million, including a $1,070.0 million letter of credit sublimit; matures on the fourth anniversary of the September 24, 2026 closing date
Initial margin of 1.750% per annum for Term SOFR loans, within a range of 1.50% to 2.00%, based on the company's debt-to-market-capitalization ratio
Minimum liquidity covenant begins with the quarter ending March 31, 2027, at 40% of commitments before the Stabilization Date and 25% after
On September 24, 2026, Celularity closed the initial phase of a financing agreement signed September 23 for up to $25.0 million of senior secured convertible notes, raising $11.01 million in gross proceeds with warrants for about 4,037,000 shares. The filing also shows a September 18 settlement with Helena in which 2,000,000 additional shares were issued, and the notes and warrants could add substantial share dilution for existing holders.
Initial closing on September 24, 2026: $11.01 million in notes, convertible at $1.50 per share into about 7,340,000 shares
Warrants for about 4,037,000 shares, exercisable at $1.50 per share for five years
Notes bear 10% interest, mature 24 months after issue, and are secured by substantially all company and subsidiary assets
Helena settlement dated September 18, 2026: 700,000 shares issued on conversion of $1.197 million at $1.71 per share, plus 2,000,000 additional shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.